If you are a B.Pharm or M.Pharm fresher eyeing regulatory affairs, the cell gene therapy regulation India 2026 Drugs Rules amendment is probably the most significant career opportunity you will see in the next five years. The Central Government just changed how advanced therapies get approved in India, and this creates an entirely new specialization track that did not exist when your seniors graduated.
I have been watching regulatory shifts for over a decade now, and I can tell you that moments like this are rare. When the FDA created its Center for Biologics Evaluation and Research (CBER) pathway for cell and gene therapies, it spawned thousands of specialized regulatory jobs in the United States. India is now setting up something similar. The question is whether you will be ready when companies start hiring.
Let me walk you through exactly what changed, what it means for your career, and how you can position yourself for these emerging roles.
What Changed: India's New Centralized Cell & Gene Therapy Regulation Explained
On July 3, 2026, the Central Government notified an amendment to the Drugs Rules, 1945 that fundamentally changes how cell therapies, gene therapies, and xenografts get approved in India. This is not a minor tweak. It is a structural overhaul that brings India closer to how the FDA and EMA regulate these advanced therapy medicinal products.
Before this amendment, cell and gene therapy products faced a confusing regulatory landscape. State Drug Licensing Authorities had overlapping jurisdiction with CDSCO. A company developing a CAR-T therapy in Bangalore might face different requirements than one in Hyderabad. Clinical trials could proceed, but the path to market authorization was unclear. Many Indian biotech companies simply focused on export markets because the domestic regulatory pathway was too fragmented.
The Drugs Rules 1945 amendment changes this completely. Cell or stem cell derived products, gene therapeutic products, and xenografts now fall under the exclusive jurisdiction of the Central Licence Approving Authority. This means CDSCO in New Delhi will handle all approvals, creating a single point of contact for companies and a standardized review process.
Why does this matter for you as a fresher? Because standardization creates predictability, and predictability creates jobs.
When the approval pathway is unclear, companies hesitate to invest in regulatory teams. Why hire a dedicated cell therapy regulatory specialist when you do not even know which authority will review your application? But when the government says "submit everything to CDSCO under these specific rules," suddenly companies need people who understand those specific rules.
The new framework is modeled loosely on the FDA's CBER approach. In the United States, the Center for Biologics Evaluation and Research handles all cell and gene therapy approvals through a dedicated Office of Tissues and Advanced Therapies. They have specialized reviewers who understand the unique challenges of these products, things like potency assays for living cells, long term follow up requirements for gene therapies, and manufacturing controls for patient specific treatments.
India is now creating a similar specialized pathway. The Central Licence Approving Authority will need to build expertise in these areas, and so will the companies submitting applications.
The expected impact on approval timelines is significant. Industry insiders estimate that the current fragmented system takes 18 to 24 months for advanced therapy approvals, when approvals happen at all. The centralized pathway should reduce this to 12 to 15 months, comparable to what we see in more mature regulatory environments.
The first products likely to benefit are CAR-T therapies for blood cancers. Several Indian companies have been developing these treatments, waiting for regulatory clarity before pushing forward with market authorization applications. Immuneel Therapeutics in Bangalore has been running clinical trials for their CAR-T product. Stempeutics Research has stem cell therapies in development. These companies will now have a clear path forward.
Gene therapies for rare genetic disorders are another category that will benefit. India has a significant patient population for conditions like thalassemia and sickle cell disease. Gene therapy approaches that have worked in Western markets could potentially be adapted for Indian patients, but only if there is a clear regulatory pathway.
The FDA's recent approval of TREGZI, the first regulatory T cell based immunotherapy for preventing graft versus host disease in blood cancer patients, shows where this field is heading globally. TREGZI uses donor immune cells to prevent serious complications after stem cell transplants. India performs thousands of stem cell transplants annually, and treatments like this could eventually become available here under the new regulatory framework.
Will This Create Jobs for Regulatory Affairs Freshers in India?
This is the question you actually care about, and I will give you an honest answer based on what I have seen in similar regulatory transitions.
Photo by Andrea Piacquadio on Pexels
Photo by Andrea Piacquadio on Pexels
In the short term, meaning 2026 to 2027, expect to see 50 to 80 new regulatory roles specifically focused on cell and gene therapy submissions. This is not a huge number compared to the thousands of pharma jobs in India, but these will be specialized positions with better career trajectories than generic regulatory roles.
Where will these jobs appear? The primary employers will be Indian biotech companies preparing CDSCO submissions for their advanced therapy products.
Biocon Biologics in Bangalore has been expanding its biosimilars portfolio and has shown interest in cell therapy manufacturing. They will need regulatory specialists who understand how to file for these products under the new rules.
Stempeutics Research, also in Bangalore, has been working on stem cell therapies for years. They have products in clinical development that will now have a clear path to market authorization. Their regulatory team will need to grow.
Immuneel Therapeutics is developing CAR-T therapies for Indian patients. They raised significant funding in recent years and will be among the first to test the new regulatory pathway. They are hiring.
Intas Pharmaceuticals in Ahmedabad has been building a biologics division. As they expand into advanced therapies, they will need regulatory expertise.
Reliance Life Sciences in Mumbai has cell therapy programs that have been waiting for regulatory clarity. The new rules could accelerate their development timelines and their hiring.
Beyond Indian biotechs, the multinational CROs operating in India will also create cell and gene therapy regulatory positions. IQVIA, Parexel, and Syneos Health all have regulatory affairs divisions in India that support global submissions. As their clients develop more cell and gene therapies, they need Indian teams who understand both the local regulatory environment and the global context.
The salary expectations for these specialized roles are higher than traditional regulatory affairs positions. A fresher in generic regulatory affairs might start at Rs 4 to 6 lakhs per annum in a mid sized company. A fresher with demonstrated knowledge of cell and gene therapy regulation could command Rs 6 to 8 lakhs, potentially more at well funded biotechs.
The medium term picture, from 2028 to 2030, is even more interesting. If the new regulatory pathway works as intended, we will see more companies entering the advanced therapy space. Global pharmaceutical companies that have been hesitant to launch cell and gene therapies in India due to regulatory uncertainty may reconsider. This could create another 150 to 200 regulatory positions over three to four years.
But I want to be honest about the risks. Regulatory reforms in India do not always proceed smoothly. The revised Schedule M implementation has faced challenges, with industry bodies like FOPE seeking clarifications from CDSCO on pharmacovigilance obligations. The new cell and gene therapy rules could face similar implementation hurdles.
If you are betting your career on this specialization, you need to stay flexible. Build skills that transfer to other regulatory areas if the advanced therapy market takes longer to develop than expected.
Related reading on ClinPath:
- FDA Cell & Gene Therapy Guidance June 2026: Career Opportunities for Indian CDM & Regulatory Freshers
- AstraZeneca Breast Cancer Drug: EU-US Split & India Regulatory Careers
- Drugs (Seventh Amendment) Rules 2026: What Schedule H2 Expansion Means for Regulatory Affairs Freshers in India
Skills That Will Make You Competitive for Cell and Gene Therapy Regulatory Roles
Let me tell you what hiring managers at Indian biotechs will actually look for when filling these positions. I have seen enough job descriptions and talked to enough regulatory heads to know what matters.
First, you need a solid foundation in biologics regulation. Cell and gene therapies are biologics, and you cannot specialize in advanced therapies without understanding the basics. This means knowing Schedule Y requirements for clinical trials, understanding the Chemistry, Manufacturing, and Controls (CMC) sections of biologics applications, and being familiar with how CDSCO reviews biological products.
If your M.Pharm curriculum covered biologics regulation, you are ahead. If it did not, you need to fill this gap through self study or short courses.